Stifel cuts Enfusion stock rating to Hold, lowers price target on acquisition

Published 13/01/2025, 15:56
Stifel cuts Enfusion stock rating to Hold, lowers price target on acquisition

On Monday, Stifel analysts downgraded Enfusion Inc (NYSE:ENFN) stock from Buy to Hold and reduced the price target to $11.25 from the previous $13.00. The decision followed Enfusion's announcement that it had reached an agreement to be acquired by Clearwater Analytics for $11.25 per share.

According to InvestingPro data, Enfusion has demonstrated solid fundamentals with a 15.78% revenue growth in the last twelve months and maintains a strong financial health score. This acquisition price is a 13% premium over the stock's closing price on Friday and values the company at approximately 6.4 times its projected FY25 enterprise value/revenue.

The analysts at Stifel noted that the acquisition agreement seemed to be a favorable outcome for Enfusion, and they regard the offered price as fair for shareholders. They also expressed their belief that the chances of a higher competing bid emerging are slim, which influenced their decision to downgrade the stock rating and adjust the price target accordingly.

Enfusion's share price is set to align with the acquisition price, reflecting the terms of the deal with Clearwater Analytics. The new price target of $11.25 per share is now in line with the agreed acquisition price, indicating Stifel's view that the stock will stabilize around this level.

The acquisition is based on a valuation that Stifel analysts find reasonable given Enfusion's financial projections. The premium offered over the last closing price before the announcement suggests that Clearwater Analytics is willing to pay a notable amount above the market valuation to secure the deal.

Investors are now observing the situation, as the acquisition represents a significant change for Enfusion. With Stifel's downgrade, the market is expected to adjust to the new developments, and trading activity will likely reflect the anticipated acquisition completion. For deeper insights into Enfusion's valuation and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.